Exposure ofmurine or human lymphocytes to L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) results in selective killing of cytotoxic lymphocytes, whereas helper T cells and B cells remain functionally intact. Cytolytic lymphocytes incubated in the presence of toxic concentrations of Leu-
Leu-OMe were found to contain membranolytic metabolites of the structure (Leu-Leu),-OMe, where n .-3. The sensitivity of cytotoxic lymphocytes to Leu-Leu-OMe was found to be dependent upon production of these metabolites by a lysosomal thiol protease, dipeptidyl peptidase I, which is present at far higher levels in cytotoxic lymphocytes than in cells without cytolytic potential or not of bone marrow origin. Thus, this granule enzyme is required for the unique effects of LeuLeu-OMe and may provide a target for the development of other immunotherapeutic agents designed to delete cytotoxic lymphocyte responses.
Cell-mediated cytotoxicity is one of the effector mechanisms generated during immune responses. A common feature of cytotoxic effector cells of lymphoid or myeloid lineage appears to be the presence of pore-forming molecules or other toxins stored within cytoplasmic lysosome-like granules (1) (2) (3) (4) . Specifically, a variety of granule proteins, including complement-like pore-forming molecules, selected serine esterases, and tumor necrosis factor-like cytotoxins, have been noted to be present in natural killer (NK) cells and cytotoxic T lymphocytes (CTL) but to be either absent or present at far lower levels in lymphocytes that are not cytolytic (5) (6) (7) (8) (9) (10) (11) (12) . The presence of cytolytic granules and associated granule proteins has been proposed to be a feature that distinguishes CTL from lymphocytes that function primarily as noncytolytic helper or suppressor cells (5, 7) . Development of techniques that utilize the unique lytic machinery of CTL to delete them selectively or modulate their function might have therapeutic value as approaches involving other phenotypic markers have not proven to be sufficiently specific.
Previous studies performed in our laboratory have described the selective effects of L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) on human or murine lymphoid cells with cytolytic potential (13) (14) (15) (16) (17) . Brief incubation of human or murine lymphocytes with Leu-Leu-OMe results in elimination of lymphocytes with cytotoxic potential, including natural killer cells and both CD4+ and CD8+ allospecific CTL, whereas helper T cells and B cells remain functionally intact.
In addition to being toxic for cytotoxic lymphocytes, LeuLeu-OMe causes death of monocytes, polymorphonuclear leukocytes, and myeloid tumor cell lines, whereas cell lines of non-bone-marrow origin appear to be completely resistant to any toxic effects of this agent (14, 16) . Of note, in murine models ofbone marrow transplantation across multiple major histocompatibility complex (MHC) and non-MHC-encoded histocompatibility barriers, brief incubation of donor cells with Leu-Leu-OMe prevents in vivo development of donor anti-host CTL and lethal graft-versus-host disease while permitting rapid engraftment and establishment of long-lived immunocompetent chimeras (15) (16) (17) . Thus, sensitivity to Leu-Leu-OMe is a characteristic oflymphoid or myeloid cells with cytotoxic potential. The present studies were designed to delineate the mechanism of Leu-Leu-OMe-mediated effects on cytotoxic lymphocytes.
MATERIALS AND METHODS
Reagents. Leu-Leu-OMe was synthesized from Leu-Leu (Sigma) as described (13) . [4,5- (PBL) were prepared by passage through nylon columns as described (13, 14) . CD8+ T cell (T8 cell)-and NK cell-enriched lymphocytes were prepared by treatment of PBL with mAb 66.1 plus complement, and CD4+ T cell-enriched lymphocytes were prepared by incubation of PBL OKT8 with mAb OKT8, "panning" on goat anti-mouse Ig-coated Petri dishes, and then treating with OKT8, Leu-llb, and complement as described (14) . In some experiments, lymphocytes were analyzed or sorted into positively selected OKT4+, CD16+, or CD19+ cell populations (>95% purity) with a fluorescenceactivated cell sorter (FACS) (FACstar; Becton Dickinson) as described (14) .
Cytotoxicity Assays. NK cell activity against K562 target cells and allospecific CTL activity against stimulator lymphoblasts were assessed in 4-hr 51Cr-release assays, and the percent specific cytotoxicity and units of lytic activity were calculated as described (14 (18) . Cathepsin B was assayed at pH 6.3 in phosphate buffer/1 mM EDTA/10 mM cysteine with (Z)-Arg-Arg-p8-naphthylamide as substrate as described (19) . Protein content was assessed by reaction with bicinchoninic acid as described (20) .
RESULTS
To determine the metabolic fate of Leu-Leu-OMe within cytotoxic lymphocytes, T8 and NK cell-enriched PBL were incubated with [3H]Leu-Leu-OMe for 15 min at 22°C, and uptake was assessed. As shown in the experiments detailed in Table 1 , cell-associated [3H]Leu-Leu-OMe could be detected after such brief incubations. When these cells were immediately lysed and 10% CC13COOH was added to precipitate higher molecular weight material, essentially all of the tritium label remained in the supernatant. However, when
[3H]Leu-Leu-OMe-loaded T8 and NK cells were incubated at 37°C for 15 to 60 min, total cell-associated tritium decreased with time, whereas an increasing fraction of the label was insoluble in 10% CCI3COOH. In other experiments (data not shown), addition of proteinase K to the cell lysate prior to CC13COOH precipitation resulted in loss of all tritium label from the precipitate. As Leu, Leu-OMe, Leu-Leu, and Leu-Leu-OMe are soluble in 10% CC13COOH, these findings suggested that after [3H]Leu-Leu-OMe uptake by T8 and NK cell-enriched PBL, a significant fraction of this peptide or its amino acid components is incorporated into a higher molecular weight peptide or protein.
Of note, as illustrated in experiment 2 of Table 1 , conversion of Leu-Leu-OMe to a CCl3COOH-insoluble product was found to be dependent on the concentration of Leu-Leu-OMe present during the initial cell incubation. Thus, the amount of (13, 14) . In additional experiments, it was found that minimal amounts of CCl3COOH-insoluble product was produced by CD4+ T cells ( (21, 23) indicated that all NK cell toxic dipeptide esters were also good substrates for the lysosomal protease DPPI. Therefore, experiments were carried out to determine whether DPPI is involved in generating a CCI3COOH-precipitable product from Leu-Leu-OMe. These experiments used Gly-Phe-CHN2, an agent reported to be a selective and specific inhibitor of DPPI (24) . Gly-Phe-CHN2 blocked generation of the CCI3COOH-insoluble product of
[3H]Leu-Leu-OMe, while having no effect on [3H]LeuLeu-OMe uptake (Table 2, experiment 3).
DPPI has been noted previously to be present at high levels in the spleens of various mammals and within human PBL, where it is present largely if not entirely within the lysosomal granule fraction (21, 23, 25) . The next experiments were undertaken to determine whether cellular content of this granule enzyme correlated with sensitivity to the toxic effects of Leu-Leu-OMe. When CD16+ NK cells were purified by FACS, they were found to contain >10-fold higher concentrations of DPPI than FACS-purified CD4+ T cells, and -20-fold higher concentrations of DPPI than CD19+ B cells (2.54, 0.19, and 0.13 nM of substrate cleaved per ,ug of protein per hr, respectively). CD8+ T cells, which contain both Leu-Leu-OMe-sensitive and Leu-Leu-OMe-resistant cells (14) , had intermediate levels of DPPI (0.62 mM substrate cleaved per gg of protein per hr). Furthermore, incubation of PBL for 60 min with 1-100 ,uM Gly-Phe-CHN2 was found to lead to >95% inhibition of intracellular DPPI activity without significantly altering activity of another lysosomal thiol protease, cathepsin B. In view of these findings, studies were performed to assess the effects of Gly-Phe-CHN2 on NK cells or CTL susceptibility to Leu-Leu-OMe toxicity.
As detailed in Table 3 and as previously reported (14), exposure of human PBL to 250 ,uM Leu-Leu-OMe results in loss of all CD16+ NK cells and the majority of CD8+ T cells, with a reciprocal enrichment of the CD4+ T-cell subset, which is largely Leu-Leu-OMe resistant. Furthermore, all NK cell function and the capacity to generate allocytotoxic T cells are lost after Leu-Leu-OMe treatment of PBL.
However, in the experiments detailed in Table 3 , Gly- tAfter Leu-Leu-OMe treatment, cells were analyzed immediately for NK cell function or were cultured for 6 days with irradiated allogeneic stimulator cells and then assayed for allospecific CTL (allo-CTL) function.
Phe-CHN2 prevented the loss of both NK cells and CTL. Thus, the fraction of viable CD16+ and CD8+ lymphocytes did not change after Leu-Leu-OMe treatment of PBL, and both NK cell function and the capacity for CTL generation were preserved. In contrast, inhibition of PBL serine protease activity with phenylmethylsulfonyl fluoride or inhibition of PBL acidic lysosomal protease activity with NH4CI or chloroquine afforded no protection from Leu-Leu-OMe toxicity (refs. 13 and 14; additional data not shown).
These studies indicate that DPPI activity within cytotoxic lymphocytes is essential for the development of the toxic effects of Leu-Leu-OMe. Therefore, additional studies were performed to assess the nature of the CCI3COOH-insoluble products generated by cytotoxic lymphocytes. More than 95% of the tritiated material present in the 10% CC13COOH precipitate of T8/NK cell-enriched lymphocytes after incubation with 250 ,uM Leu-Leu-OMe was found to be soluble in methanol. TLC separation of this material (Fig. 1) revealed that >80% of the tritium was found in fractions corresponding in elution pattern with Leu4-OMe (59.7%), Leu6-OMe (12.2%), Leu6 (4.2%), and another major unknown peak (5.2% of total cpm). In view of the known propensity of DPPI to form polymers of the general structure (R1-R2),,-OMe and the increasing hydrophobicity and elution rate of (LeuLeu),-OMe polymers demonstrated in this experiment, it seemed likely that this latter peak represented tritiated Leu8-OMe. Ofadditional note, larger molecular weight proteins are in general insoluble in either methanol alone or the solvent system utilized in the experiment detailed in Fig. 1 . Therefore, these findings strongly suggest that molecules of the general structure (Leu-Leu),-OMe, where n 2 2, are the predominant CCI3COOH-insoluble transpeptidation products generated by DPPI-rich cytotoxic lymphocytes.
In view of these findings, experiments were performed to assess whether such DPPI-catalyzed polymerization products have direct cytolytic activity. Human RBC that contain no detectable levels of DPPI (personal observation) or other lysosomal enzymes were used as targets. When 51Cr-labeled RBC were incubated with various concentrations of Leu2-OMe or Leu4-OMe, no RBC lysis was observed (Fig. 2) . The nonesterified peptides Leu2, Leu4, and Leu6 also had no lytic activity at concentrations of 0-5 mM (data not shown). However, Leu6-OMe caused significant levels of RBC lysis (Fig. 2) . Moreover, addition of exogenous DPPI and .250
,AM Leu-Leu-OMe induced significant RBC lysis, whereas products of the structure (Leu-Leu),,-OMe. Finally, the demonstration that RBC were lysed by Leu6-OMe alone or DPPI ,r Leu-Leu-OMe alone had any discernible + Leu-Leu-OMe indicated that DPPI-catalyzed Leun RBC membrane integrity (Fig. 2) .
Leu-OMe metabolites of structure (Leu-Leu),,-OMe, where n 2 3, were responsible for the DPPI-mediated toxicity of DISCUSSION Leu-Leu-OMe. The capacity of DPPI-catalyzed products of Leu-Leu-OMe )w that Leu-Leu-OMe-mediated toxicity for such as Leu6-OMe to induce lysis of human RBC is likely to ocytes is dependent on the conversion of be related to the detergent properties previously described membranolytic products of structure (Leufor molecules composed of a long hydrocarbon chain at-3) by the acyltransferas activity of the tached to a protonated amine terminus (28) higher than that present in Leu-Leu-OMe-resistant cell types when normalized to total cell protein content. Furthermore, we have been unable to detect significant production of CCl3COOH-insoluble polymerization products of LeuLeu-OMe within cell types resistant to this agent. These findings may be related to differences in the quantity or activity of the DPPI-like enzymes present in Leu-Leu-OMesensitive and Leu-Leu-OMe-resistant cells. Other characteristics of the microenvironment present in these cells may also contribute to the apparent cellular specificity of the toxic effects of Leu-Leu-OMe, including differences in the acidification capacity of the cells or the presence of other proteases that leads to rapid degradation of Leu-Leu-OMe or of (Leu-Leu),,-OMe polymers before membranolytic concentrations of such DPPI-catalyzed products of Leu-Leu-OMe are accumulated. The characteristics of DPPI as noted in the current and previous studies indicate that this enzyme is distinct from other granule proteases previously noted to be selectively expressed by NK cells and CTL. All previously described CTL-specific granule proteases appear to be serine esterases (5, (7) (8) (9) 11) . DPPI is resistant to inhibition by the serine esterase inhibitor phenylmethylsulfonyl fluoride. Moreover, inhibition of this enzyme by specific and nonspecific covalent binding to a sulfhydryl group apparently associated with its active site clearly indicates that this enzyme is a thiol protease and as such is the first enzyme of its class that has been found to be expressed at higher levels in NK cells and CTL than in noncytotoxic lymphocytes. Furthermore, the high levels of this enzyme that are uniquely found in cytolytic lymphocytes suggest that DPPI may serve an as-yetundefined important function within these cells. As shown in the present study, however, preincubation of PBL with a specific and irreversible inhibitor of this enzyme has no inhibitory effect on subsequent NK function. Whereas DPPI appears to play no requisite direct role in cytolytic effector function, it remains to be determined whether DPPI might play an indirect role by processing other cytolytic effector molecules, or, possibly, in the induction or maintenance of the function of cytolytic effector cells.
Among the various monoclonal antibodies or pharmacologic reagents used to delete or inactivate functional subsets of immune effector cells, Leu-Leu-OMe has been demonstrated previously to have a unique spectrum of activity (13) (14) (15) (16) (17) . The present studies demonstrate that the selective toxicity of this agent for cytotoxic lymphocytes and various myeloid cells is related to the presence of high levels of the lysosomal thiol protease, dipeptidyl peptidase I, within these cells, which converts Leu-Leu-OMe to membranolytic products of structure (Leu-Leu),,-OMe where n -3. These findings not only identify another granule protease that is selectively enriched in cytotoxic effector cells but also delineate a unique mechanism for targeting of immunotherapeutic reagents.
